Cassava Sciences Inc vs State Street PDR S&P Retail ETF — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while State Street PDR S&P Retail ETF trades at $90.62. The key difference: State Street PDR S&P Retail ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | XRT | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $90.88 |
52-Week Low | $1.09 | $77.28 |
Enterprise Value | -$33.43M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
XRT (SPDR S&P Retail ETF) trades at $90.47, up 3.1% with strong bullish technical signals from moving averages. The ETF shows neutral sentiment from oscillators but faces mixed fundamental data with key valuation ratios unavailable. Recent retail sector news highlights consumer spending resilience despite economic headwinds, with the ETF positioned to capture broad retail exposure.
Outlook remains cautiously optimistic given bullish technical indicators and positive retail sales trends, though valuation concerns and macroeconomic pressures present risks. The ETF's diversification across retail stocks offers exposure to sector recovery potential while mitigating individual company risks.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →